You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

300 Results
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Sep 2021
Regimen
Intent: Adjuvant
Funding:
New Drug Funding Program
    Nivolumab - Adjuvant Treatment for Completely Resected Stage IIB or IIC Melanoma
New Drug Funding Program
    Nivolumab - Adjuvant Treatment for Completely Resected Stage III or IV Melanoma
Oct 2024
Regimen
Intent: Palliative
May 2019
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - Metastatic Renal Cell Carcinoma
Aug 2024
Drug
Other Name(s): Lonsurf®
Nov 2024
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nivolumab plus Ipilimumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
Aug 2024
Blog post
The science of gathering and reporting on cancer burden data in Ontario began nearly a century ago, several years before the organization now known...
Oct 2018

Pages